DelveInsight Presents Renal Cell Carcinoma Abstracts Overview: Key ESMO 2024 Findings

ESMO 2024 brought an exciting wave of insights into renal cell carcinoma treatment, showcasing the latest advancements in immunotherapy, precision medicine, and combination treatments. Researchers presented groundbreaking abstracts that highlighted novel approaches targeting hard-to-treat RCC subtypes, improving patient outcomes, and tackling resistance mechanisms. 

From innovative biomarkers that predict treatment response to promising new drug combinations enhancing overall survival, this year's findings have the potential to reshape RCC management. ESMO 2024 was truly a testament to the relentless pursuit of better, more effective solutions for patients with RCC. The summary of each abstract is given below

Abstract Number: LBA73

Title: Tivozanib–Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma (RCC) Following 1 or 2 Prior Therapies including an Immune Checkpoint Inhibitor (ICI) – Results of the Phase III TiNivo-2 Study

Results from the Phase III TiNivo-2 trial, presented at ESMO 2024, revealed that the tivozanib–nivolumab combination did not achieve its primary endpoint. The absence of clinical benefits with this immunotherapy combination suggests that sequential ICI therapy should be avoided outside clinical trials for advanced RCC. However, this finding supports the growing preference for using FOTIVDA monotherapy at a daily dose of 1.34 mg as a second-line option for patients who have progressed after prior ICI combination therapy.

AVEO’s setback in Phase III mirrors BMS’s earlier results, where OPDIVO failed to significantly extend disease-free survival in localized RCC patients in the Phase III CheckMate-914 trial, reported in January 2024. In contrast, Merck has shown progress in RCC treatment with the FDA approval of its HIF-2α inhibitor, WELIREG, in December 2023, for advanced disease patients previously treated with a PD-1 inhibitor and a VEGF blocker.

Dive deep into the results from the Phase III TiNivo-2 trial presented at the ongoing ESMO 2024. Get Detailed Insight Here

Abstract Number: 1690O

Title: NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a Phase 1/2 study

The preliminary findings from a Phase I/II study of NKT2152, presented at ESMO 2024, show promising efficacy, with an objective response rate (ORR) of 24% and a median progression-free survival (PFS) of 7.5 months in a heavily pretreated patient group. The safety profile aligns with that of similar agents, underscoring NKT2152's potential as a valuable option in this challenging oncology field.

Advanced RCC treatment is a highly competitive landscape with key players and therapies leading the market. MSD ’s WELIREG (belzutifan), another oral HIF-2α inhibitor targeting the same pathway in RCC, has gained ground since receiving FDA approval in December 2023 for treating advanced RCC in adults who have previously received PD-1/PD-L1 inhibitor and VEGF-TKI therapies. This approval introduced a new therapeutic class to the RCC market, a first in nearly ten years.

NKT2152's preliminary outcomes indicate its potential as a valuable addition to the treatment arsenal for advanced ccRCC.

Get the complete result analysis of NKT2152. Read Now

Abstract Number: 1706P

Title: Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multi-center multi-country Phase 1/2a expansion cohort

At ESMO 2024, data showed that 23ME-00610 is safe and well-tolerated at a 1400 mg dose every three weeks in patients with clear cell renal cell carcinoma (ccRCC). The drug demonstrated anti-tumor activity in patients who were resistant to immunotherapy, with a favorable safety profile, complete engagement of its peripheral target, and pharmacokinetics supporting the three-week dosing interval.

As ccRCC patients frequently develop resistance to both immune checkpoint inhibitors (ICIs) and VEGF inhibitors, 23ME-00610 could provide a valuable option as a second-line or later treatment, meeting a significant unmet need. Further trials will be essential to optimize its role and assess its position within the competitive landscape. Other companies advancing innovative immunotherapies for ccRCC include AstraZeneca , Bristol Myers Squibb , and Roche , who are investigating next-generation ICIs, bispecific antibodies, and additional immunomodulatory strategies.

Will 23ME-00610 be a game changer in the ccRCC therapeutic market? Find Out

Abstract Number: 1691P 

Title: Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients (pts) with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated efficacy and safety results from CheckMate 67T

The abstract presented at the ESMO Congress 2024 compares subcutaneous nivolumab (NIVO-SC) and intravenous nivolumab (NIVO-IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC). It reveals that NIVO-SC demonstrated non-inferiority to NIVO-IV in terms of efficacy, with similar progression-free survival and overall survival outcomes. Furthermore, the subcutaneous formulation showed a more favorable safety profile with a reduced incidence of infusion-related reactions, making it an attractive alternative for patients who require immune checkpoint inhibitors for ccRCC. The study highlights the potential benefits of NIVO-SC in improving treatment convenience and patient experience.

Abstract Number: 1692P

Title: A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma

The Phase Ib/IIa trial for PM8002 (BNT327), a bispecific antibody targeting PD-L1 and VEGF-A, demonstrated promising efficacy in treating advanced renal cell carcinoma (RCC). In the study, PM8002 showed objective response rates (ORR) of 25% for clear cell RCC (ccRCC) and 36.4% for non-clear cell RCC (nccRCC). The monotherapy also resulted in favorable disease control rates (DCR) and median progression-free survival (mPFS) times. Adverse events were reported, but most were manageable

Get an in-depth analysis of all the renal cell carcinoma abstracts presented at the ESMO 2024 @ Renal Cell Carcinoma Analysis and Insights

Renal cell carcinoma is the eighth most common cancer in the United States, early-stage disease can often be asymptomatic, and 16% of patients present with metastatic RCC. Renal cell carcinoma accounts for 2% of global cancer diagnoses and deaths. 

Renal cell carcinoma is the most common type of kidney cancer. Approximately, 20–40% will progress to Stage IV. As per DelveInsight Business Research LLP analysis, the incident cases of renal cell carcinoma were highest in the United States among the 7MM in 2023.

The treatment landscape of advanced renal cell carcinoma is governed by targeted therapies and immunotherapies. Some FDA-approved renal cell carcinoma drugs are AFINITOR (everolimus), AVASTIN (bevacizumab), BAVENCIO (avelumab), WELIREG (belzutifan), and others.

Key players, such as Merck Sharp & Dohme, Xynomic Pharmaceuticals, NiKang Therapeutics Inc. , Arcus Biosciences , Corvus Pharmaceuticals , and others are involved in developing drugs for RCC. Apart from these, several oncolytic virus manufacturers are working toward the development of potential therapies for renal cell carcinoma to fulfill the unmet medical needs of the currently used therapeutics. The promising emerging renal cell carcinoma oncolytic virus therapies include GeneMedicine ’s GM 103 (Phase I/II) and SillaJen ’s PEXA-VEC (Phase II).  The predicted launch of these oncolytic virus therapies will give a boost to the renal cell carcinoma market in the future.

Keen to know more about renal cell carcinoma? Get all the insights at the Renal Cell Carcinoma Market Report

Stay updated with DelveInsight Business Research LLP as we unveil the scientific advancements paving the way for the future of oncology!